NZ617003A - Method to use gene expression to determine likelihood of clinical outcome of renal cancer - Google Patents

Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Info

Publication number
NZ617003A
NZ617003A NZ61700311A NZ61700311A NZ617003A NZ 617003 A NZ617003 A NZ 617003A NZ 61700311 A NZ61700311 A NZ 61700311A NZ 61700311 A NZ61700311 A NZ 61700311A NZ 617003 A NZ617003 A NZ 617003A
Authority
NZ
New Zealand
Prior art keywords
apold1
cell carcinoma
renal cell
likelihood
gene expression
Prior art date
Application number
NZ61700311A
Other languages
English (en)
Inventor
Steven Shak
Michael C Kiefer
Frederick L Baehner
Dejan Knezevic
Tara Maddala
Audrey Goddard
Wayne Cowens
Joffre Baker
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Priority to NZ705645A priority Critical patent/NZ705645A/en
Publication of NZ617003A publication Critical patent/NZ617003A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Computing Systems (AREA)
  • Artificial Intelligence (AREA)
  • Probability & Statistics with Applications (AREA)
  • Algebra (AREA)
  • Computational Mathematics (AREA)
NZ61700311A 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer NZ617003A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ705645A NZ705645A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US34623010P 2010-05-19 2010-05-19
NZ600268A NZ600268A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Publications (1)

Publication Number Publication Date
NZ617003A true NZ617003A (en) 2015-04-24

Family

ID=44258831

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ61700311A NZ617003A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ705645A NZ705645A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ719474A NZ719474A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ600268A NZ600268A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ705645A NZ705645A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ719474A NZ719474A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ600268A NZ600268A (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Country Status (12)

Country Link
US (4) US9551034B2 (enExample)
EP (5) EP3029155A3 (enExample)
JP (5) JP6286124B2 (enExample)
AU (1) AU2011203977B2 (enExample)
CA (3) CA2783858C (enExample)
DK (1) DK3178944T3 (enExample)
ES (2) ES3027507T3 (enExample)
IL (6) IL219978A (enExample)
MX (3) MX375138B (enExample)
NZ (4) NZ617003A (enExample)
SG (1) SG181806A1 (enExample)
WO (1) WO2011085263A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
CA2843756A1 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
US10195174B2 (en) 2011-10-24 2019-02-05 Signalchem Lifesciences Corporation Carbonic anhydrase IX-related markers and use thereof
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
US10181008B2 (en) * 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
EP3047040B1 (en) * 2013-09-17 2019-12-11 Lucence Life Sciences Pte Ltd. Multigene assay for prognosis of renal cancer
WO2016034611A1 (en) * 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
US20180044736A1 (en) * 2015-02-03 2018-02-15 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
PL3589754T3 (pl) 2017-03-01 2023-10-09 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
US11427873B2 (en) * 2018-08-10 2022-08-30 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
MX2021008797A (es) 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
KR20230148819A (ko) 2021-02-26 2023-10-25 리제너론 파마슈티칼스 인코포레이티드 글루코코르티코이드 및 안지오포이에틴-유사 7 (angptl7) 억제제를 이용한 염증의 치료
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN118711678B (zh) * 2024-08-22 2025-12-12 暨南大学附属第一医院（广州华侨医院） 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) * 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
NZ520095A (en) * 2000-01-13 2004-05-28 Genentech Inc Novel Stra6 polypeptides, nucleic acids, antibodies, compositions and methods of treatments for inhibiting tumor cell growth
DE10126344A1 (de) * 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
AU2001294842A1 (en) * 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
US20060088823A1 (en) * 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7470509B2 (en) * 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
DK3115470T3 (en) 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
CA2501131A1 (en) * 2002-10-04 2004-04-22 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
MXPA05014220A (es) 2003-07-02 2006-03-09 Novartis Ag Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
US20050130193A1 (en) 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
WO2005117943A2 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
BRPI0608429A2 (pt) 2005-02-18 2009-12-29 Wyeth Corp método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006124022A1 (en) * 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
ES2624863T3 (es) * 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2612287C (en) * 2005-06-15 2011-01-25 Pfizer Limited Substituted arylpyrazoles for use against parasites
KR101446626B1 (ko) * 2005-09-02 2014-10-06 도레이 카부시키가이샤 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법
ATE531820T1 (de) 2005-09-14 2011-11-15 Human Genetic Signatures Pty Gesundheitszustandstest
CA2622852A1 (en) * 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
JP5984324B2 (ja) 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
BRPI0620695A2 (pt) 2005-12-16 2011-11-22 Genentech, Inc método para tratar um tumor do tipo glioma, métodos de prognóstico e/ou diagnóstico de glioma, método de monitoramento ou diagnóstico, método para inibir o tamanho ou crescimento de um tumor do tipo glioma, métodos para tratar terapeuticamente, método para determinar o nìvel de expressão de marcadores determinantes de glioma ("gdm") de pn, prolif ou mes, método para prognosticar o tempo de sobrevida, método para diagnosticar a severidade de um tumor do tipo glioma e uso
WO2007146668A2 (en) * 2006-06-06 2007-12-21 University Of Massachusetts Use of imp3 as a prognostic marker for cancer
JP5725711B2 (ja) * 2006-08-10 2015-05-27 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療法を有する患者の同定、評価、および治療のための方法
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US9034574B2 (en) 2006-12-27 2015-05-19 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
US8541170B2 (en) 2008-11-17 2013-09-24 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
WO2010149640A2 (en) * 2009-06-26 2010-12-29 Noviogendix Research B.V. Molecular markers in kidney cancer
JP5964752B2 (ja) 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
WO2012174282A2 (en) 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CA2843756A1 (en) 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
US10892038B2 (en) 2021-01-12
SG181806A1 (en) 2012-07-30
IL219978A (en) 2017-04-30
IL270151B (en) 2021-03-25
EP3029155A3 (en) 2016-08-31
EP2524055A4 (en) 2013-06-05
EP3831964B1 (en) 2025-04-16
EP3831964A3 (en) 2021-10-20
WO2011085263A3 (en) 2012-01-12
JP7307602B2 (ja) 2023-07-12
AU2011203977A1 (en) 2012-06-21
JP6286124B2 (ja) 2018-02-28
CA2783858A1 (en) 2011-07-14
MX375138B (es) 2025-03-06
IL262100B (en) 2019-11-28
NZ719474A (en) 2018-07-27
EP3029155A2 (en) 2016-06-08
US20170121780A1 (en) 2017-05-04
JP2016174600A (ja) 2016-10-06
MX2020009704A (es) 2020-10-07
CA3128103A1 (en) 2011-07-14
JP2021177761A (ja) 2021-11-18
JP2017148059A (ja) 2017-08-31
IL280689B (en) 2022-01-01
JP2013516195A (ja) 2013-05-13
US20220051755A9 (en) 2022-02-17
IL219978A0 (en) 2012-07-31
IL251635B (en) 2018-04-30
IL256335B (en) 2018-12-31
MX2012007882A (es) 2012-08-03
EP2524055A2 (en) 2012-11-21
AU2011203977B2 (en) 2015-02-05
IL262100A (en) 2018-11-29
US12412642B2 (en) 2025-09-09
CA3256492A1 (en) 2025-11-29
IL280689A (en) 2021-03-25
EP3831964A2 (en) 2021-06-09
DK3178944T3 (da) 2019-08-12
EP3561078A1 (en) 2019-10-30
JP7385630B2 (ja) 2023-11-22
CA2783858C (en) 2021-09-14
US20210166790A1 (en) 2021-06-03
US20110171633A1 (en) 2011-07-14
JP6546214B2 (ja) 2019-07-17
EP3178944A3 (en) 2017-09-13
US20240096451A1 (en) 2024-03-21
NZ705645A (en) 2016-05-27
IL251635A0 (en) 2017-06-29
WO2011085263A2 (en) 2011-07-14
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
MX341866B (es) 2016-09-06
ES3027507T3 (en) 2025-06-16
CA3128103C (en) 2025-11-18
US11776664B2 (en) 2023-10-03
US9551034B2 (en) 2017-01-24
NZ600268A (en) 2014-08-29
JP2019162150A (ja) 2019-09-26
ES2741379T3 (es) 2020-02-10

Similar Documents

Publication Publication Date Title
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
NZ599194A (en) Methods to predict clinical outcome of cancer
NZ593228A (en) Gene expression markers (inhba) for colorectal cancer prognosis
NZ629538A (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
NZ610482A (en) Predictors of patient response to treatment with egf receptor inhibitors
HK1201881A1 (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB2483810B (en) Methods for correlating clonotypes with diseases in a population
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
NZ627864A (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
WO2012079059A3 (en) Post-treatment breast cancer prognosis
WO2010088688A3 (en) Diagnosis of in situ and invasive breast cancer
WO2008103971A3 (en) Prostate cancer survival and recurrence
WO2019094780A3 (en) Non-coding rna for detection of cancer
WO2015091575A3 (en) Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
WO2012059750A3 (en) Factors
WO2011085276A3 (en) Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
WO2012149245A3 (en) Genomic signatures of metastasis in prostate cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 JAN 2018 BY FB RICE

Effective date: 20151007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20171219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2021 BY COMPUTER PACKAGES INC

Effective date: 20191218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20201218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2023 BY COMPUTER PACKAGES INC

Effective date: 20211217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2024 BY COMPUTER PACKAGES INC

Effective date: 20221217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2025 BY COMPUTER PACKAGES INC

Effective date: 20231217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2026 BY COMPUTER PACKAGES INC

Effective date: 20241217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2027 BY COMPUTER PACKAGES INC

Effective date: 20251217